0.39
-0.025(-6.10%)
Currency In USD
| Previous Close | 0.41 |
| Open | 0.39 |
| Day High | 0.4 |
| Day Low | 0.37 |
| 52-Week High | 3 |
| 52-Week Low | 0.22 |
| Volume | 1.75M |
| Average Volume | 8.41M |
| Market Cap | 6.07M |
| PE | -0.44 |
| EPS | -0.87 |
| Moving Average 50 Days | 0.52 |
| Moving Average 200 Days | 0.81 |
| Change | -0.03 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $3.8 as of July 12, 2025 at a share price of $0.385. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $11.16 as of July 12, 2025 at a share price of $0.385.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
GlobeNewswire Inc.
Jul 09, 2025 12:30 PM GMT
Application Update Based on Extensive Review of DataGLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
GlobeNewswire Inc.
Jun 25, 2025 12:30 PM GMT
Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batch
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
GlobeNewswire Inc.
Jun 17, 2025 12:00 PM GMT
GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r